SRS' Head of Life Sciences, Donald Morrissey, joins Morgan Lewis for a lunchtime discussion reviewing the recently released 2012 SRS Life Sciences M&A Study.
The most important new drugs, devices and other life sciences products are routinely being developed and commercialized under M&A agreements involving long-term earn-out and other milestone-driven contingent payment structures. The negotiation of these structures and post-closing management can have a powerful impact on shareholder returns in these types of transactions. The presentation will provide useful insight into life sciences exits, including deal terms and earn-out outcomes.
Tuesday, November 6, 2012
Please RSVP by November 5, 2012 to email@example.com.